{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:14:58Z","timestamp":1778696098585,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473286"],"award-info":[{"award-number":["81473286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81503114"],"award-info":[{"award-number":["81503114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31010300010339"],"award-info":[{"award-number":["31010300010339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.biopha.2019.108906","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T09:26:55Z","timestamp":1556875615000},"page":"108906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation"],"prefix":"10.1016","volume":"115","author":[{"given":"Yu-Meng","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Xin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Zi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong-Tong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong-Yu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei-Bei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Guang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2019.108906_bib0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2119\/molmed.2015.00148","article-title":"Aspirin\u2019s active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses","volume":"21","author":"Choi","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2019.108906_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12967-016-0961-2","article-title":"miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40","volume":"14","author":"Guo","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2019.108906_bib0015","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1210\/jc.2016-2917","article-title":"Preconception low-dose aspirin restores diminished pregnancy and live birth rates in women with low-grade inflammation: a secondary analysis of a randomized trial","volume":"102","author":"Sjaarda","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2019.108906_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.phrs.2016.04.001","article-title":"Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model","volume":"107","author":"Tarantino","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2019.108906_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10787-015-0253-0","article-title":"Efficacy of disintegrating aspirin in two different models for acute mild-to-moderate pain: sore throat pain and dental pain","volume":"24","author":"Voelker","year":"2016","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.biopha.2019.108906_bib0030","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.108906_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2019.108906_bib0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","article-title":"Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis","volume":"385","author":"Elmariah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2019.108906_bib0045","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2019.108906_bib0050","doi-asserted-by":"crossref","first-page":"16830","DOI":"10.1073\/pnas.1406997111","article-title":"Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs","volume":"111","author":"Li","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.108906_bib0055","doi-asserted-by":"crossref","first-page":"14583","DOI":"10.1073\/pnas.251543298","article-title":"A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin","volume":"98","author":"Ouellet","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.108906_bib0060","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1124\/dmd.113.051805","article-title":"Aspirin hydrolysis in human and experimental animal plasma and the effect of metal cations on hydrolase activities","volume":"41","author":"Bahar","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108906_bib0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-014-0226-2","article-title":"Effects of alcohol on human carboxylesterase drug metabolism","volume":"54","author":"Parker","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2019.108906_bib0070","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1124\/jpet.106.110577","article-title":"Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol","volume":"319","author":"Tang","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2019.108906_bib0075","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/bmc.2694","article-title":"Review of HPLC methods and HPLC methods with mass spectrometric detection for direct determination of aspirin with its metabolite(s) in various biological matrices","volume":"26","author":"Mullangi","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2019.108906_bib0080","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm300038c","article-title":"Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent","volume":"55","author":"Shan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2019.108906_bib0085","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fphar.2018.00643","article-title":"Evaluation of tolerability, pharmacokinetics and pharmacodynamics of vicagrel, a novel P2Y12 antagonist, in healthy Chinese volunteers","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jpba.2017.11.019","article-title":"Development and validation of a sensitive and rapid UHPLC-MS\/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma","volume":"149","author":"Liu","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2019.108906_bib0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2018.10.011","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing","volume":"127","author":"Liu","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.108906_bib0100","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fphar.2017.00846","article-title":"Arylacetamide deacetylase is involved in vicagrel bioactivation in humans","volume":"8","author":"Jiang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11095-013-1158-5","article-title":"Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel","volume":"31","author":"Qiu","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2019.108906_bib0110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/jps.23394","article-title":"Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs","volume":"102","author":"Qiu","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.108906_bib0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fphar.2016.00366","article-title":"Species comparison of pre-systemic bioactivation of vicagrel, a new acetate derivative of clopidogrel","volume":"7","author":"Qiu","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/FJC.0000000000000529","article-title":"Overcoming clopidogrel resistance: three promising novel antiplatelet drugs developed in China","volume":"70","author":"Xie","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/FJC.0000000000000622","article-title":"Aspirin attenuates the bioactivation of and platelet response to vicagrel in mice","volume":"72","author":"Jia","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0130","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1160\/TH17-04-0250","article-title":"Refinement of mouse protocols for the study of platelet thromboembolic responses in vivo","volume":"117","author":"Rauzi","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.biopha.2019.108906_bib0135","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12906-016-1463-8","article-title":"Antiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from cordyceps militaris ex vivo, in vivo, and in vitro","volume":"16","author":"Kwon","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.biopha.2019.108906_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1160\/TH17-07-0519","article-title":"Inhibitory effects of an orally active thromboxane A2 receptor antagonist, nstpbp5185, on atherosclerosis in ApoE-deficient mice","volume":"118","author":"Huang","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.biopha.2019.108906_bib0145","article-title":"Studies on new activities of enantiomers of 2-(2-Hydroxypropanamido) benzoic acid: antiplatelet aggregation and antithrombosis","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2019.108906_bib0150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/FJC.0000000000000428","article-title":"Enhanced platelet response to clopidogrel in abcc3-deficient mice due to its increased bioactivation","volume":"68","author":"Tai","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0155","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jth.13238","article-title":"Interleukin-10 does not modulate clopidogrel platelet response in mice","volume":"14","author":"Yin","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2019.108906_bib0160","first-page":"555","article-title":"Evaluation of the antiplatelet aggregation effects of diltiazem","volume":"1","author":"Khalid","year":"2016","journal-title":"J. Pharmacol. Clin. Res."},{"key":"10.1016\/j.biopha.2019.108906_bib0165","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1751-553X.2012.01420.x","article-title":"P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease","volume":"34","author":"Timur","year":"2012","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.biopha.2019.108906_bib0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/0300060516675681","article-title":"Effects of atorvastatin on ADP-, arachidonic acid-, collagen-, and epinephrine-induced platelet aggregation","volume":"45","author":"Zhao","year":"2017","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.biopha.2019.108906_bib0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/FJC.0000000000000449","article-title":"W1, a novel oral antiplatelet agent with less resistance than clopidogrel","volume":"69","author":"Ge","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.biopha.2018.07.023","article-title":"Therapeutic effects of JLX001 on cerebral ischemia through inhibiting platelet activation and thrombus formation in rats","volume":"106","author":"Yan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2019.108906_bib0185","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/bmc.973","article-title":"Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers","volume":"22","author":"Bae","year":"2008","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2019.108906_bib0190","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/bmc.3573","article-title":"Simultaneous quantitation of acetylsalicylic acid and clopidogrel along with their metabolites in human plasma using liquid chromatography tandem mass spectrometry","volume":"30","author":"Chhonker","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2019.108906_bib0195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/bmc.1209","article-title":"Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study","volume":"23","author":"Xu","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.biopha.2019.108906_bib0200","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3797\/scipharm.1206-12","article-title":"Simultaneous determination of atorvastatin and aspirin in human plasma by LC-MS\/MS: its pharmacokinetic application","volume":"80","author":"Gajula","year":"2012","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.biopha.2019.108906_bib0205","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-0031-1296203","article-title":"Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization: tandem mass spectrometry detection","volume":"61","author":"Nirogi","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.biopha.2019.108906_bib0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jchromb.2016.08.039","article-title":"Simultaneous determination of curcumin diethyl disuccinate and its active metabolite curcumin in rat plasma by LC-MS\/MS: Application of esterase inhibitors in the stabilization of an ester-containing prodrug","volume":"1033-1034","author":"Ratnatilaka Na","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2019.108906_bib0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejps.2017.09.040","article-title":"Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans","volume":"111","author":"Yoshida","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.108906_bib0220","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1124\/dmd.111.043067","article-title":"Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse","volume":"40","author":"Kobayashi","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108906_bib0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2019.108906_bib0230","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bioorg.2018.09.018","article-title":"Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen","volume":"81","author":"Huttunen","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2019.108906_bib0235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejps.2015.07.006","article-title":"Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases","volume":"78","author":"Fukami","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2019.108906_bib0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/dmd.115.068221","article-title":"Arylacetamide deacetylase is responsible for activation of prasugrel in human and dog","volume":"44","author":"Kurokawa","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108906_bib0245","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/dmd.107.020248","article-title":"The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2","volume":"36","author":"Williams","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2019.108906_bib0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.intimp.2016.11.028","article-title":"Didymin ameliorates hepatic injury through inhibition of MAPK and NF-\u03baB pathways by up-regulating RKIP expression","volume":"42","author":"Huang","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2019.108906_bib0255","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000452524","article-title":"Raf kinase inhibitory protein down-expression exacerbates hepatic fibrosis in vivo and in vitro","volume":"40","author":"Huang","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2019.108906_bib0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1124\/dmd.115.066290","article-title":"Human intestinal Raf kinase inhibitor protein (RKIP) catalyzes prasugrel as a bioactivation hydrolase","volume":"44","author":"Kazui","year":"2016","journal-title":"Drug Metab. Dispos."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219308169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219308169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:36:47Z","timestamp":1778693807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219308169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":52,"alternative-id":["S0753332219308169"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108906","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"108906"}}